Galactosylgalactosylglucosylceramidase
"Galactosylgalactosylglucosylceramidase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the hydrolysis of a ceramidetrihexoside to a ceramidedihexoside plus galactose.
Descriptor ID |
D002517
|
MeSH Number(s) |
D08.811.277.450.410.150
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Galactosylgalactosylglucosylceramidase".
Below are MeSH descriptors whose meaning is more specific than "Galactosylgalactosylglucosylceramidase".
This graph shows the total number of publications written about "Galactosylgalactosylglucosylceramidase" by people in this website by year, and whether "Galactosylgalactosylglucosylceramidase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2006 | 2 | 3 | 5 |
2007 | 4 | 0 | 4 |
2008 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Galactosylgalactosylglucosylceramidase" by people in Profiles.
-
Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets. 2008 Aug; 9(8):653-61.
-
Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
-
Upregulation of the human alkaline ceramidase 1 and acid ceramidase mediates calcium-induced differentiation of epidermal keratinocytes. J Invest Dermatol. 2008 Feb; 128(2):389-97.
-
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
-
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008 Feb; 61(2):231-42.
-
Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther. 2007 Jul; 15(7):1259-63.
-
Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes. 2006 Sep; 55(9):2579-87.
-
Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
-
New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett. 2006 Aug 21; 580(19):4751-6.
-
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.